The chromosomal gene aph(3)-IIb, encoding an aminoglycoside 3-phosphotransferase in Pseudomonas aeruginosa, was cloned and overexpressed in Escherichia coli. The APH(3)-IIb enzyme was purified as a monomer in a two-step procedure and was shown to phosphorylate its substrates at the C-3-OH position, with k cat /K m values of 0.4 ؋ 10 4 to 36 ؋ 10 4 M ؊1 s ؊1 .
Despite emerging bacterial resistance, aminoglycosides remain vital weapons against some multiresistant pathogens, such as Pseudomonas aeruginosa. The primary mechanism of resistance to aminoglycosides is the bacterial acquisition of enzymes that structurally modify these antibiotics. Among these enzymes, aminoglycoside 3Ј-phosphotransferases [APH(3Ј)s], which catalyze transfer of the ␥-phosphoryl group of ATP to the 3Ј-hydroxyl of many drugs, are widely represented (5, 12) . Ten years ago, the chromosomal gene aph(3Ј)-IIb was identified in P. aeruginosa (2) , and it was believed that the "uniform resistance" of P. aeruginosa to kanamycin is greatly contributed to by the presence of this gene. aph(3Ј)-IIb is located in the pseudomonal genome in an operon downstream of the hpaA gene, which encodes an autoregulator involved in the metabolism of 4-hydroxyphenylacetic acid (4-HPA) (13) . Interestingly, unlike most other aminoglycoside-modifying enzymes, which are constitutive, the hpaA-aph(3Ј)-IIb operon was found to be induced by 4-HPA. The present study describes the cloning, simple purification, and initial kinetic and biochemical characterization of the APH(3Ј)-IIb enzyme.
The aph(3Ј)-IIb gene (GenBank accession number X90856) was amplified from genomic DNA of P. aeruginosa ATCC 27538 by PCR (N-terminal primer, 5Ј-CGTCATATGGGTCC ATGGATGATGCAGCCACCTCC-3Ј; C-terminal primer, 5Ј-CTGCTGCAGCACGGATCCTAGAAGAACTCGTCCAAT AG-3Ј; the start codon is in bold). A 30-l PCR mixture included 100 ng of chromosomal DNA, 10 ng/l of each primer, 7.5% (vol/vol) dimethyl sulfoxide (DMSO), 0.2 mM deoxynucleoside triphosphates, ThermoPol buffer, and 2 units of Vent DNA polymerase (New England Biolabs). The PCR product was purified, digested with NcoI and BamHI, cloned into NcoI-BamHI-restricted plasmid pET11d (Novagen) to yield pET11d-aph(3Ј)-IIb, and sequenced.
The procedure for purification of APH(3Ј)-IIb was adapted and optimized from protocols previously reported for other APH enzymes (7, 10) . A 2-liter culture of Escherichia coli BL21(DE3) CodonPlus-RP (Stratagene) carrying the pET11d-aph(3Ј)-IIb plasmid, in Luria-Bertani medium containing 100 g/ml ampicillin and 25 g/ml kanamycin A, was grown with isopropyl-␤-D-thiogalactopyranoside (2 mM) to a final turbidity of 2.5 (optical density at 600 nm). After harvesting, the cells were resuspended in 16 ml buffer (50 mM Tris-HCl [pH 8.0], 5 mM EDTA, 200 mM NaCl, 0.1 mM dithiothreitol, and 1 mM phenylmethylsulfonyl fluoride), disrupted (two passages through a French press), and centrifuged. The supernatant was diluted fourfold with buffer A1 (50 mM Tris-HCl [pH 8.0], 1 mM EDTA) and loaded onto a Q-Sepharose column (Pharmacia). The proteins were eluted with 1 column volume (CV) of a 0-to-20% linear gradient of buffer B1 (A1 plus 1 M NaCl), followed by 2 CVs of 20% B1, 6 CVs of a 20-to-50% B1 gradient, and 3 CVs of 50% B1. APH(3Ј) active fractions were pooled, diluted threefold with buffer A2 (50 mM Tris-HCl, pH 7.4), and loaded onto a neomycin-conjugated affinity column (prepared by coupling neomycin B with N-hydroxysuccinimideactivated Sepharose [HiTrap-HP, 5 ml; GE Healthcare], according to the manufacturer's protocol). The protein was eluted with 22 CVs of 0-to-100% buffer B2 (A2 plus 1.2 M KCl). Active fractions were pooled and concentrated to yield 18 mg of purified protein ( Fig. 1 ; also Table S1 in the supplemental material). The M r was determined using a Superdex 75 (10/30) gel filtration column (buffer A2 plus 100 mM KCl).
The enzymatic activity was monitored as previously described (3, 11) . K m and k cat values were determined by nonlinear regression analysis using GraFit 5.0 (6). MICs were determined using the double-microdilution method according to the CLSI (formerly NCCLS) (8) . The preparative phosphorylation of neomycin B was done with purified APH(3Ј)-IIb as previously described for kanamycin A (10) .
During the cloning and expression of the APH(3Ј)-IIb pro-tein, we encountered two problems which arose from the high GC content of the aph(3Ј)-IIb gene (2) . The addition of DMSO to the PCR mixture was essential for successful amplification of the gene (1). Indeed, we were able to identify this gene in the standard P. aeruginosa strains ATCC 27853 and PAO1, as well as in six other clinical isolates, only after the addition of DMSO. Moreover, the APH(3Ј)-IIb enzyme contains five prolines encoded by the rare codon CCC; therefore, the overproduction of the protein in the CodonPlus-RP E. coli strain (which coexpresses the rare proline tRNA) allowed higher expression yields. In addition, the use of freshly transformed cells to inoculate the starter culture was crucial for overexpression of the protein, probably because of the unfavorable consumption of ATP by this enzyme in the bacterium, leading to selective pressure against maintenance of the plasmid (4). Using anion-exchange and affinity columns, we obtained 18 mg of purified protein from a 2-liter culture. The purified APH(3Ј)-IIb protein is a monomer in solution with a M r of about 31,000, in agreement with its calculated M r (29,900). Unlike APH(3Ј)-Ia and APH(3Ј)-IIIa, which undergo spontaneous dimerization in the absence of dithiothreitol (7, 10) , no dimerization was observed for APH(3Ј)-IIb. Based on the measured k cat /K m values (Table 1) , amikacin is the poorest substrate for the enzyme. This decrease in specificity for amikacin is caused primarily by its poor ability to saturate the enzyme, as judged from its elevated K m value (440 M) compared to the K m values of the other aminoglycosides (3.1 to 17.5 M).
Indeed, unlike other substrates tested, amikacin has a (S)-4-amino-2-hydroxy-butyryl substitution at the N-1 position, which is believed to be unfavorable for interactions with the enzyme active site. Lividomycin A, tobramycin, and gentamicin, which lack C-3Ј-OH, were not substrates for APH(3Ј)-IIb. The observed kinetic data are consistent with the antibacterial data ( Table 2 ). Both P. aeruginosa and E. coli strains harboring APH(3Ј)-IIb are resistant to good substrates but are sensitive to those which were not substrates of the enzyme (tobramycin and gentamicin) or poor substrates (amikacin). The identical MICs of amikacin (12 g/ml) against the two isogenic strains of E. coli indicate that the reason for the observed sensitivity of the E. coli strain harboring APH(3Ј)-IIb is the inferior activity of this enzyme towards amikacin, rather than reduced permeability of amikacin. In fact, comparison of its K m value (440 M) with the MICs of 16 and 4 M (12 and 3 g/ml) against E. coli and P. aeruginosa, respectively, suggests that the bacteria are killed at far lower concentrations before the enzyme's full catalytic potential is reached. This observation with amikacin and the substrate profile of the purified APH(3Ј)-IIb are similar to those for the previously reported enzyme APH(3Ј)-IIa (9) .
Monitoring the time courses of APH(3Ј)-IIb-catalyzed phosphorylations by proton-coupled 31 P nuclear magnetic resonance ( 31 P-NMR) [50 mM Tris-HCl buffer (pD 7.1), 40 mM KCl, 10 mM MgCl 2 , 132 mM ATP, 150 l purified APH(3Ј)-IIb (0.3-U/ml stock solution), and 44 mM aminoglycoside in a total volume of 0.65 ml D 2 O] (3) revealed a single phosphate resonance (doublet, with a typical three-bond POOOCOH coupling constant [J] of Ϸ8 Hz [inset in Fig. 2] , indicative of phosphate attached to a carbon bearing only one hydrogen) for all substrates but no phosphorylation product for lividomycin, indicating that APH(3Ј)-IIb is highly specific for C-3Ј-OH. As such, APH(3Ј)-IIb differs from other APH(3Ј) enzymes, which perform multiple phosphorylations on neomycin B and C-5Љ phosphorylation on lividomycin (3, 11) . For example, protoncoupled 31 P-NMR experiments with APH(3Ј)-IIIa revealed two phosphorylation sites for neomycin B and multiple phosphorylations on other synthetic derivatives (3).
To confirm our results, as an example, the product of phosphorylation of neomycin B by the APH(3Ј)-IIb enzyme was isolated, and the modification was confirmed to occur solely at the 3Ј-OH ( Fig. 2 ; see also Table S2 in 
